Journal of Clinical Oncology - ASCO Publications
Oct 2, 2024 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
When a Monoclonal Gammopathy Is Not Multiple Myeloma
Apr 8, 2022 · A monoclonal gammopathy is a laboratory-based finding that is being increasingly recognized in the aging population. Until recently, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was based on studies from Olmsted County, Minnesota, and from Scandinavian health records, indicating an incidence of approximately 1%. 1 The majority …
Current and Future Management of HER2-Positive Metastatic …
Jun 2, 2021 · Advanced breast cancer with overexpression and/or amplification of human epidermal growth factor receptor 2 (HER2) is a clinically aggressive subtype with poor survival outcomes. 1,2 However, with the introduction of trastuzumab, the survival rates have greatly improved. 1 Trastuzumab binds to the extracellular domain IV of HER2 preventing its …
Cannabis Use in Patients With Cancer: A Clinical Review
Jun 24, 2022 · Of the 15.5 million Americans living with cancer, 1 moderate to severe pain (0-10 numerical rating score ≥ 5) is experienced by more than a third because of consequences of cancer, its treatments, or both. 2 According to a large, longitudinal study done by the American Cancer Society, pain was among the top three symptoms contributing the greatest negative …
Recent Advances in the Management of Metastatic Prostate Cancer
In 2021, it is estimated that 26% of new noncutaneous cancer cases will be because of prostate cancer resulting in 11% of cancer-related deaths in the United States, making it the most common malignancy in men and the second leading cause of cancer mortality. 1 Following onset of metastatic disease, the disease is invariably fatal with a 5-year survival rate of only 30%.
Managing Metastatic Melanoma in 2022: A Clinical Review
Feb 8, 2022 · The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) is a serine/threonine protein kinase that was described in 1983 as an oncogene playing a critical role in the RAS-RAF-MEK-ERK mitogen–activated protein kinase (MAPK) cell signaling pathway, with high frequencies of BRAF point mutations discovered in melanoma and other human cancers. 6,7 The …
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO ...
Kidney cancer will be diagnosed in 79,000 US patients in 2022 (50,290 men and 28,710 women) and will account for 13,920 deaths (8,960 men and 4,960 women). 1 Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC, and it continues to be a major source of morbidity and mortality. 1,2 This disease has been a bellwether tumor type, with novel classes …
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Oct 17, 2022 · Colorectal cancer (CRC) is the third most common type of cancer diagnosed worldwide. 1 Almost 150,000 new cases and more than 50,000 deaths from CRC are reported each year in the United States. 2 In recent decades, the overall incidence of CRC has decreased among older adults because of screening and lifestyle factors; however, at the same time, …
Management of Aromatase Inhibitor–Induced Musculoskeletal …
Aug 11, 2020 · Abstract. Aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) were first recognized as a distinct entity in 2001, 5 years after the approval of the first aromatase inhibitor, anastrozole. Musculoskeletal symptoms can severely affect patients’ quality of life and also lead to premature discontinuation of aromatase inhibitor therapy.
Bringing Life to Death: The Need for Honest, Compassionate, and ...
Mar 24, 2020 · Research demonstrates that patients prefer early initiation of advance directive discussions; however, many patients do not have these discussions with either primary care physicians or specialists. 5-7 Avoidance of clinician-led EOL conversations can deny the patient and family the opportunity for meaningful plans for the present. In addition, avoidance can …